title: Arterial thrombosis with anti-phospholipid antibodies induced by infliximab.
authors.affiliation: UCB Lyon I, Inserm U851, Clinical Immunology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69495, Pierre Bénite Cedex, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Nosbaum
authors.forename: Catherine
authors.initials: C
authors.lastname: Goujon
authors.forename: Bertrand
authors.initials: B
authors.lastname: Fleury
authors.forename: Isabelle
authors.initials: I
authors.lastname: Guillot
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Nicolas
authors.forename: Frédéric
authors.initials: F
authors.lastname: Bérard
mesh_terms: D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D016736:Antiphospholipid Syndrome / Q000139:chemically induced*; D005260:Female; D005263:Femoral Artery / Q000473:pathology; D006801:Humans; D007083:Iliac Artery / Q000473:pathology; D007155:Immunologic Factors / Q000009:adverse effects*; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy; D013927:Thrombosis / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000974:Antibodies, Antinuclear; D017152:Antibodies, Antiphospholipid; D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab